A utocrine production of growth factors to which a malignant cell expresses receptors has long been a postulated mechanism for tumor growth (1) and has recently been shown to occur in several hematological malignancies. Acute myeloid leukemia blast cells produce granulocyte/macrophage CSF and express receptors for this cytokine, which promotes clonogenic growth (2) . Chronic malignancies of B cells consistently show evidence of autocrine growth, since the neoplastic cells of multiple myeloma (3) produce IL6, while B chronic lymphocytic leukemia (B-CLL)t and hairy cell leukemia (HCL) produce and respond to a variety of cytokines, including ILA (4, 5), IL6 (6, 7), and TNF (8, 9). Levels of constitutive cytokine production are variable (6, 7, 10), but induction of high levels can be attained after exposure to cytokine proteins (8) .
If these malignancies are dependent on autocrine growth factors for survival, interruption of the autocrine loop would be of therapeutic value. TNF promotes viability of cells ob-1 Abbreviations used in this paper B-CLL, B chronic lymphocytic leukemia ; HCL, hairy cell leukemia.
tained from patients with HCL or B-CLL (8) and also induces these malignant B cells into cell cycle so that culture with TNF protein induces expression of mRNA for c-myc, coo, and cjun (11) . TNF also promotes increased thymidine incorporation (8, 12) . We have previously shown that IFN-01 almost completely abrogates TNF-induced enhancement of thymidine uptake in cells from patients with B-CLL and HCL, while IFN-y has no significant effect (8) . IFN-ot has been shown to have therapeutic activity in HCL and B-CLL in vivo (13, 14) , and we now show that IFN-ci may exert this therapeutic effect by reducing expression of mRNA for autocrine growth-promoting cytokines in these malignant cells.
Materials and Methods
Patient Details. 12 patients with B lymphoproliferative disorders (eight with BCLL, three with BCLL/PL, and one with HCL) were studied on 18 occasions in various parts of this study. Clinical data and diagnosis (FAB classification) (15) Lymphocyte Separation . Venous blood taken into preservativefree heparin was layered onto lymphoprep (Nyegaard, Oslo, Norway), and the mononuclear cells in the interface were depleted of monocytes by adherence to plastic for 90 min at 37°C . The population was then depleted of T cellsby double E-rosetting. The composition of the resulting PBL population was assessed by immunophenotyping, and contained <0 .5% CD3' T cells or CD14' monocytes and (in patients 2-12) >98% CD5' B-CLL cells (Table 1 ) . All cell preparation and culture was undertaken in RPMI 1640 (Gibco Laboratories, Uxbridge, UK) supplemented with 2 mM glutamine (Gibco Laboratories) and 100 IU/ml streptomycin/penicillin (Gibco Laboratories) in the presence of 10% FCS (Sera-Lab, Crawley, Sussex, UK). Cells were cultured in medium containing 250 U/ml TNF or 250 U/ml TNF and 500 U/ml IFN-(X, and were harvested at various time points for RNA extraction . The doses of cytokines chosen were those at which optimum effect had been demonstrated in thymidine incorporation assays (8).
Phenotyping. Phenotyping was performed by indirect immunofluorescence using a microplate method (16) . OKT3 (CD3 ; Ortho Diagnostic Systems, Inc., Westwood, MA), RFT1 (CD5, a gift Immunophenotype was determined pre-depletion of monocytes and T cells.
of Professor G. Janossy, Immunology Department, Royal Free Hospital), and Leu-M3 (CD14; Becton Dickinson & Co., Mountain View, CA) were used as first layer mAb, while fluorescein-or rhodamine-conjugated goat anti-mouse Ig (Southern Biotechnology Associates, Birmingham, AL) was used for the second layer. 500 cells were analyzed using an immunofluorescent microscope . All purified B-CLL preparations contained >98% CD5' B cells, while >98% of HCL patient Tdepleted lymphocytes had morphological and tartrate-resistant acid phosphotase staining characteristics of HCL cells.
mRNA Extraction . Cytoplasmic RNA was extracted from PBLs using the detergent lysis method (17) . Briefly, cells were washed in PBS and resuspended in hypotonic buffer (10 mM Tris HCI, pH 7.8, 150 mM NaCl) containing 10 mM vanadyl ribonuclease complex (Bethesda Research Laboratories, Gaithersburg, MD) and 1% NP-40 (Shell Chemicals) . The nuclei were pelleted by centrifugation, and the cytoplasmic extract was treated with 1% SDS, followed by phenol chloroform extraction and salt ethanol precipitation. RNA was quantified and either size fractionated on a 1% agarose/formaldehyde gel and transferred overnight to nitrocellulose or applied directly to nitrocellulose via a slot blot apparatus (Schleicher and Schuell, Inc.) .
Filters were baked for 2 h at 80°C and then prehybridized in 50% formamide, 5 x SSC, 5 x Denhardt's solution, and 50 Fcg/ml denatured salmon sperm DNA at 42'C for 4-8 h. cDNA probes were labeled by random oligopriming using [' 2P]dCTP (Amersham International, Amersham, UK), and hybridization was carried out for 16 h at 42°C . Filters were washed twice in 2x SSC/0.1% SDS, at room temperature and twice in 0.2x SSC/0.1% SDS at 65°C, and exposed to Fuji RX film for 1-7 d at -70°C with intensifying screens. Autoradiograms were scanned using a chromoscan (LKB Instruments, Inc., Gaithersburg, MD). Integrals obtained from the linear phase of the film were normalized with respect to the control probe.
Actinom growth loop, we stimulated CLL and HCL cells with TNF, and measured the effect of IFN-a on steady-state cytokine mRNA concentrations. Fig. 1 shows detailed time courses of TNF mRNA expression in one patient with HCL (A), two patients with B-CLL (B and C), and one patient with BCLLPL (D) . In the presence of exogenous TNF protein alone, TNF mRNA levels rose above constitutive levels and peaked by 24-40 h. However, culture of cells in the presence of both TNF and IFN-oz substantially abrogated this rise in cytokine message. IFN-a has a similar effect on the accumulation of mRNA for three other cytokines, IL-6 (Fig. 2 a) , and IL1a and 11710 (Fig. 2 b) . Fig. 3 summarizes these data for all patients examined in this part of the study and illustrates cytokine mRNA at 24 h of culture in the presence of both TNF and IFN-a or TNF alone. The data show consistent reduction in cytokine mRNA levels in the presence of IFN-a.
Mechanism by which IFN-a Downregulates mRNA . Suppression of cytokine mRNA accumulation did not represent a global effect on cellular steady-state accumulation of mRNA : levels of mRNA for structural proteins such as tubulin were unaffected by IFN-a. Moreover, levels of mRNA encoding the enzyme 2-5 A synthetase substantially increased after culture with IFN-a (Fig . 4) . 2-5A synthetase is a potent inducer of ribonucleases (18) , which in turn increase degradation of certain mRNA species. We determined if increased degradation was indeed the mechanism by which IFN-a reduced steady-state cytokine mRNA . Fresh mRNA transcription was inhibited with actinomycin D, allowing measurement of the half-life of cytokine mRNA . Cytokine mRNA is short lived in these malignant B cells compared with the , and an absence of or low levels of mRNA for 2-5A synthetase were present; after culture with IFN-a (lanes 2, 4, 6, and 8), there was induction of mRNA for 2-5A synthetase.
This study investigated one mechanism by which IFN-ac may exert its therapeutic activity in B-CLL and HCL. The results of the current study show that IFN-ct can interrupt the production of autocrine growth factors by HCL and B-CLL cells by reducing accumulation ofmRNA for a number of cytokines, including IIr1a and a, TNF-a, and ID6. At the same time, IFN-a increases the expression of mRNA for the enzyme 2-5A synthetase, a ribonuclease activator. Analysis of the kinetics of cytokine mRNA production shows that levels fall shortly after the rise of2-5A synthetase mRNA (Figs. 1 and 2) . The fall in cytokine mRNA may therefore be a consequence of induction ofribonuclease activity by 2-5A synthetase, particularly as TNF mRNA half-life is reduced in the presence of IFN-a.
While accumulation ofmRNA for a number of cytokines is reduced by IFN-a, mRNA levels for structural proteins such as tubulin are not detectably affected. Differences in the sensitivity of the mRNAs for cytokine and structural proteins to IFN-a-induced ribonucleases may reflect differences in their 3' untranslated regions. These 3' sequences regulate message instability (19, 20) and may confer susceptibility to IFN-a-induced ribonucleases . Preliminary observations show that these in vitro effects of IFN-a are reproduced in vivo. Treatment of patients with IFN-a rapidly reduces the content of TNF mRNA in B-CLL cells, while producing a corresponding increase in cellular 2-5A synthetase activity (De Mel et al., unpublished observations).
We suggest that IFN-a exerts its therapeutic effects by reducing endogenous growth factor production rather than by enhancing antileukernic host cytotoxic effector mechanisms, as was first suggested (21) . No correlation has been found between effector function and therapeutic response during IFN-a treatment ofpatients with HCL/B-CLL (22) . Moreover, the leukemic target cells are almost entirely resistant to the cytotoxic effects of the activated killer cells generated during IFN-a treatment (22, 23) . It is more difficult to assess the relative importance of each cytokine downregulated by IFN-a treatment . TNF (8, 12, 24), IIr1(5), BCGF (25) (26) (27) , and IIr6 (28) may all be capable of inducing growth and/or differentiation in B-CLL/HCL cells, so that the overall therapeutic effects of IFN-a may result from the downregulation of a multiplicity of endogenous growth factors .
If this concept of the mechanism of the effects of IFN-a in the B lymphoproliferative diseases is correct, then the variable sensitivity ofindividual neoplasms such as HCL, B-CLL, non-Hodgkins lymphoma, and myeloma to IFN-a treatment may reflect variation in dependence on autocrine growth loops. Moreover, within each disease, the sensitivity of an individual patient may depend on the degree to which the malignant lymphocytes depend for their growth on autocrine factors and how readily IFN-a induces 2-5 A synthetase activity. Our interpretation also leads to the prediction that antibodies to cytokine proteins or their receptors would have an additional contribution to make to the therapeutic action ofIFN-a.
